.After a few years in biotech, Mike Quigley, Ph.D., is going back to the pharma fold, occupying the leading science location at Sanofi.Quigley is going to begin Sept. 30 as the French Big Pharma’s chief medical policeman and global head of research, Sanofi said to Intense Biotech in an emailed claim.Quigley is actually switching out Frank Nestle, M.D., who left Sanofi this springtime surrounded by a global overhaul of the company’s R&D unit. Nestle, who devoted eight years along with the pharma, jumped over to Deerfield Administration, where he presently serves as a partner on the rehabs staff and also CEO of the agency’s therapeutic exploration and growth functions.
Quigley will participate in Sanofi coming from a San Francisco-based biotech that resides in secrecy, according to his LinkedIn profile. He’s currently listed as the firm’s founder, head of state and also CEO.Given that August 2021, Quigley has actually worked as a project partner at SV Health and wellness Investors, a medical care fund supervisor along with existing financial investments in biotechs including BioAge, Cerevance, Dualitas Therapeutics as well as Nimbus Therapies, to name a few. Quigley formerly stored the top location at Dualitas, a biotech that remains in secrecy, depending on to STAT.The soon-to-be Sanofi leader likewise previously helmed Therini Bio, an immunotherapy biotech operating to create therapies for neurodegenerative illness steered through general problems.Just before spending the last handful of years in biotech, Quigley has an also longer record in Large Pharma, very most recently working as Gilead’s senior vice president of research the field of biology up until the summer season of 2021.
Prior to that, he clocked in more than 4 years across numerous leadership functions at Bristol Myers Squibb as well as served as a scientific supervisor at Johnson & Johnson’s Janssen upper arm before that.Sanofi stated Quigley’s goal in his brand-new part would certainly be to “maximize our possibility of effectiveness via optimal cooperations around our company and also beyond, taking best-in-class technology along with cultivating and also sourcing new industry-leading skill along with a devotion to variety,” according to an interior memorandum gotten by STAT.